Key result
Concomitant administration of monovalent, bivalent, or trivalent OPV with RV1 significantly lowered rotavirus seroconversion compared to staggered administration (47% vs 63%; P<.001).
Why the study?
Does concomitant administration of OPV reduce RV1 immunogenicity in healthy infants compared to staggered administration?
Population
409 healthy infants in Matlab, Bangladesh
Comparison
Concomitant administration of monovalent… vs Staggered administration of RV1 and OPV
Design
RCT, randomized to receive 3 doses of monovalent OPV type 1 or bivalent OPV…
Follow-up
≥3 weeks after the second RV1 dose
Authors
Loading...
Staggered OPV-RV1 dosing may improve rotavirus immunogenicity in infants; confirms live oral vaccine interference in this RCT.
RCT (n=409)
randomized
No
Does concomitant administration of OPV reduce RV1 immunogenicity in healthy infants compared to staggered administration?
Absolute Event Rate: 47% vs 63%
p-value: p=< .001
Coadministration of OPV and RV1 on the same day significantly lowers rotavirus vaccine immunogenicity compared to staggered administration.
Emperador et al. (2015) conducted an RCT in Healthy infants (n=409). Concomitant administration of RV1 and OPV vs. Staggered administration of RV1 and OPV (≥1 day apart) was evaluated on Rotavirus seroconversion (4-fold rise in immunoglobulin A titer) (p=< .001). Concomitant administration of monovalent, bivalent, or trivalent OPV with RV1 significantly lowered rotavirus seroconversion compared to staggered administration (47% vs 63%; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: